Revi® System Demonstrates Significant and Sustained Quality of Life Benefits Across All Domains for the Majority of Patients with Urgency Urinary Incontinence at 24 Months
BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and developer of the Revi® System, a patient-centric tibial neuromodulation solution for urgency urinary incontinence (UUI), announced today 24-month Quality of Life (QoL) results from the OASIS pivotal study showing sustained and clinically meaningful improvements. The research was presented at the annual meeting of the American Urological Association (AUA) in Las Vegas.
BlueWind Medical Announces Peer-Reviewed Data Showing Excellent Durability of Results for Revi® System at Two Years
BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and developer of the Revi® System, a patient-centric solution for urgency urinary incontinence (UUI), announced today the publication of two-year results from the pivotal OASIS study in the March 2025 issue of the Journal of Urology.
BlueWind Medical Announces Favorable CMS Decision for 2025 Reimbursement Rates for Revi® System’s Implantable Tibial Neuromodulation Therapy
BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and developer of the Revi® System for urge urinary incontinence (UUI), announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a favorable payment adjustment for the 2025 Medicare Hospital Outpatient Prospective Payment and Ambulatory Surgical Center (ASC) Payment Systems Rule, favorably impacting reimbursement rates for the Revi System.
New Research from BlueWind Medical Shows Implantable Tibial Neuromodulation (iTNM), such as the Revi® System, as Effective Alternative to Sacral Neuromodulation (SNM) for Overactive Bladder and Urge Urinary Incontinence
BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and developer of the Revi® System, a patient-centric solution for urge urinary incontinence (UUI), announced today the publication of a comprehensive meta-analysis in the October issue of the peer-reviewed publication Advances in Therapy. “Sacral and Implantable Tibial Neuromodulation for the Management of Overactive Bladder: A Systematic Review and Meta-analysis” highlights the efficacy and safety of iTNM for treating UUI and overactive bladder (OAB), supporting it as a compelling alternative to sacral neuromodulation (SNM). The findings are particularly relevant to the Revi System, which is based on iTNM technology.
Two-Year Revi® Therapy Data Reinforce Sustained Efficacy and Safety of Implantable Tibial NeuroModulation in Managing Urgency Urinary Incontinence
BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and the developer of the Revi® System, today announced that new two-year data from its OASIS pivotal study were presented at the American Urogynecologic Society (AUGS) Pelvic Floor Disorders (PFD) Week 2024 in Washington, D.C., October 22-25 and the International Continence Society (ICS) 2024 Annual Meeting in Madrid, October 23-25.
